2017201620152014 | 2013 | 2012 | 2011


Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.

PET-CT Alone May Not Distinguish Richter Transformation in CLL

PET-CT Alone May Not Distinguish Richter Transformation in CLL

Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.

Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma

Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma

Patients who presented with an MRD level below 10-6 had a significantly improved PFS compared with patients who were above this threshold.

Nilotinib Dose, Frequency Reduction Maintains Efficacy in Chronic Myeloid Leukemia

Nilotinib Dose, Frequency Reduction Maintains Efficacy in Chronic Myeloid Leukemia

Researchers analyzed the outcomes of 67 patients with BCR-ABL1-positive CML in chronic phase who had an MMR on nilotinib twice daily and who then switched to a once-daily reduced-dose regimen.

Elotuzumab Meets Primary Endpoint of ORR for Newly Diagnosed Multiple Myeloma

Elotuzumab Meets Primary Endpoint of ORR for Newly Diagnosed Multiple Myeloma

Ninety-five percent of patients received elotuzumab at the increased rate of 5 mL/min without any incidence of IR.

Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia

Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia

Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.

Imatinib Increases Complete Response Rate, Decreases HSCT Allocation in Pediatric ALL

Imatinib Increases Complete Response Rate, Decreases HSCT Allocation in Pediatric ALL

Based on findings from previous studies (COG AALL0031 and EsPhALL 2004-2009), researchers are assessing the association of continuous imatinib plus chemotherapy with the reduced need for HSCT.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs